Vigil Neuroscience Inc
Prices are adjusted according to historical splits.
- Today's Low:
- Today's High:
- Open Price:
- 52W Low:
- 52W High:
- Prev. Close:
- Market Cap.:
- $220.26 million
- Book Value:
- Revenue TTM:
- Operating Margin TTM:
- Gross Profit TTM:
- Profit Margin:
- Return on Assets TTM:
- Return on Equity TTM:
Vigil Neuroscience Inc had its IPO on 2022-01-07 under the ticker symbol VIGL.
The company operates in the Healthcare sector and Biotechnology industry. Vigil Neuroscience Inc has a staff strength of 61 employees.
Shares of Vigil Neuroscience Inc opened at $4.91 at the start of the last trading session i.e. 2023-09-12.
The stocks traded within a range of $4.86 - $5.38, and closed at $5.22.
This is a +7.19% increase from the previous day's closing price.
A total volume of 67,031 shares were traded at the close of the day’s session.
In the last one week, shares of Vigil Neuroscience Inc have slipped by -14.98%.
Vigil Neuroscience Inc's Key Ratios
Vigil Neuroscience Inc has a market cap of $220.26 million, indicating a price to book ratio of 2.1202 and a price to sales ratio of 0.
In the last 12-months Vigil Neuroscience Inc’s revenue was $0 with a gross profit of $0 and an EBITDA of $-78980000. The EBITDA ratio measures Vigil Neuroscience Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Vigil Neuroscience Inc’s operating margin was 0% while its return on assets stood at -29.7% with a return of equity of -49.88%.
In Q2, Vigil Neuroscience Inc’s quarterly earnings growth was a positive 0% while revenue growth was a positive 0%.
Vigil Neuroscience Inc’s PE and PEG Ratio
- Forward PE
- Trailing PE
Its diluted EPS in the last 12-months stands at $-2.06 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Vigil Neuroscience Inc’s profitability.
Vigil Neuroscience Inc stock is trading at a EV to sales ratio of 0 and a EV to EBITDA ratio of -3.7049. Its price to sales ratio in the trailing 12-months stood at 0.
Vigil Neuroscience Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $175.41 million
- Total Liabilities
- $8.17 million
- Operating Cash Flow
- Capital Expenditure
- Dividend Payout Ratio
Vigil Neuroscience Inc ended 2023 with $175.41 million in total assets and $0 in total liabilities. Its intangible assets were valued at $175.41 million while shareholder equity stood at $153.84 million.
Vigil Neuroscience Inc ended 2023 with $0 in deferred long-term liabilities, $8.17 million in other current liabilities, 4000.00 in common stock, $-180103000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $58.74 million and cash and short-term investments were $150.16 million. The company’s total short-term debt was $804,000 while long-term debt stood at $0.
Vigil Neuroscience Inc’s total current assets stands at $155.72 million while long-term investments were $0 and short-term investments were $91.42 million. Its net receivables were $0 compared to accounts payable of $2.36 million and inventory worth $0.
In 2023, Vigil Neuroscience Inc's operating cash flow was $0 while its capital expenditure stood at $122000.
Comparatively, Vigil Neuroscience Inc paid $0 in dividends in 2023.
Other key metrics
- Current Trading Price
- 52-Week High
- 52-Week Low
- Analyst Target Price
Vigil Neuroscience Inc stock is currently trading at $5.22 per share. It touched a 52-week high of $16.77 and a 52-week low of $16.77. Analysts tracking the stock have a 12-month average target price of $19.71.
Its 50-day moving average was $7.12 and 200-day moving average was $9.74 The short ratio stood at 13.09 indicating a short percent outstanding of 0%.
Around 1017.7% of the company’s stock are held by insiders while 8879.7% are held by institutions.
Frequently Asked Questions About Vigil Neuroscience Inc
Similar Industry Stocks (Biotechnology)
Vigil Neuroscience, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel immune cells of the brain. Its lead candidate is VGL101, a human monoclonal antibody agonist targeting human triggering receptor expressed on myeloid cells 2 and is in a Phase 2 proof-of-concept trial in patients with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP), a rare and fatal neurodegenerative disease. The company is also conducting IND-enabling studies with a novel small molecule TREM2 agonist program to treat common neurodegenerative diseases associated with microglial dysfunction, with an initial focus on Alzheimer’s disease in genetically defined subpopulations. Vigil Neuroscience, Inc. was incorporated in 2020 and is headquartered in Watertown, Massachusetts.